First Tracks Biotherapeutics (TRAX) Stock Price, News & Analysis

Company Overview

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies which modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033 and ANB101. First Tracks Biotherapeutics is based in SAN DIEGO.

Key Stats

• Today's Range: $30.11 to $33.31
• 50-Day Range: $30.59 to $47.92
• 52-Week Range: $14.72 to $49.91
• Volume: 1.48 million shs
• Average Volume: 738,758 shs
• Market Capitalization: $1.14 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $65.17
• Consensus Rating: Moderate Buy

First Tracks Biotherapeutics Stock Analysis - MarketRank™

First Tracks Biotherapeutics scored higher than 44% of companies evaluated by MarketBeat, and ranked 445th out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

First Tracks Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on no strong buy ratings, 12 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

First Tracks Biotherapeutics has a consensus price target of $65.17, representing about 103.6% upside from its current price of $32.01.

Amount of Analyst Coverage

First Tracks Biotherapeutics has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for First Tracks Biotherapeutics are expected to grow in the coming year, from ($4.31) to ($3.84) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of First Tracks Biotherapeutics is -17.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of First Tracks Biotherapeutics is -17.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.59% of the float of First Tracks Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

First Tracks Biotherapeutics has a short interest ratio ("days to cover") of 7.5.

Change versus previous month

Short interest in First Tracks Biotherapeutics has recently increased by 11.65%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

First Tracks Biotherapeutics does not currently pay a dividend.

Dividend Growth

First Tracks Biotherapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for First Tracks Biotherapeutics this week, compared to 3 articles on an average week.

Search Interest

5 people have searched for TRAX on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, First Tracks Biotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,758,287.00 in company stock.

Percentage Held by Institutions

First Tracks Biotherapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/08/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:TRAX
• CIK: 2091349
• Web: www.firsttracksbio.com
• Phone: 858-362-6295
• Fax: N/A
• Employees: 104
• Year Founded: N/A

Price Target and Rating

• Average Price Target for First Tracks Biotherapeutics: $65.17
• High Price Target: $100.00
• Low Price Target: $31.00
• Potential Upside/Downside: +103.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.79
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.28
• Quick Ratio: 14.28

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 35,730,000
• Free Float: N/A
• Market Cap: $1.14 billion
• Optionable: N/A
• Beta: N/A